Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Tafinlar

(TA-fin-lar)
A drug used alone or with trametinib to treat low-grade glioma (a type of brain tumor) in children aged 1 year and older and certain types of anaplastic thyroid cancer, non-small cell lung cancer, melanoma, and other solid tumors that have a certain mutation (change) in the BRAF gene. It is also being studied in the treatment of other types of cancer. Tafinlar blocks certain proteins made by the mutated BRAF gene, which may help keep cancer cells from growing. It is a type of kinase inhibitor. Also called dabrafenib mesylate.
More Information
Search NCI's Dictionary of Cancer Terms